Abbott Laboratories Reports Strong First Quarter Performance

Abbott Laboratories announced a robust start to 2025, with first-quarter revenue climbing 4% year-over-year to $10.4 billion. The company's net earnings saw an impressive 8.2% increase, totaling $1.3 billion, while diluted earnings per share (EPS) rose by 8.6% to $0.76.

CEO Highlights Diversified Business Model as Key to Success

Robert Ford, CEO of Abbott, attributed the company's strong performance to its diversified business model. "Abbott's ability to deliver top-tier sales and EPS growth, even in uncertain times, underscores the strength of our diversification and execution," Ford stated. The company remains confident in its 2025 outlook, reaffirming its guidance for organic sales growth, adjusted operating margin, and adjusted diluted EPS.